Compare Quest Diagnostics Inc (DGX) vs 8x8 Inc (EGHT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs 8x8 Inc — how do they compare? Quest Diagnostics Inc trades at $230.72 (market cap $25.06B), while 8x8 Inc trades at $2.2 (market cap $307.65M). The key difference: Quest Diagnostics Inc is far larger — about 81.5× 8x8 Inc's market cap, and Quest Diagnostics Inc pays a 1.52% dividend while 8x8 Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and 8x8 Inc for 16 Days on average.
| DGX | EGHT | |
|---|---|---|
Market Cap | $25.06B | $307.65M |
Volume | 927,361 | 750,629 |
Sector | Health | Technology |
52-Week High | $247.45 | $2.76 |
52-Week Low | $173.49 | $1.59 |
Typical Hold Time | 56 Days | 16 Days |
Enterprise Value | $30.82B | $574.57M |
Dividend Yield | 1.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.03% with consistent earnings beats in recent quarters. The stock shows bearish technical signals despite strong fundamentals including 9.19% net margins and 14.35% ROE. Recent developments include a partnership with Apple Health app and concerns about Medicare reimbursement cuts affecting future revenue streams.
The outlook remains cautiously optimistic with a $250 consensus price target representing 8.3% upside potential. Key opportunities include growth in advanced diagnostics and consumer testing demand, while risks center on Medicare payment reductions and competitive pressures in the diagnostic services market.
EGHT trades at $2.14, down 1.38% today, with a bullish technical signal from moving averages and strong momentum indicators. The company shows improving fundamentals with three consecutive quarterly EPS beats and projected profitability in 2026. Recent news highlights cost-saving client implementations and AI product growth, while analyst consensus targets $19.77 with mixed ratings.
The outlook suggests potential upside if profitability materializes as projected, supported by operational efficiency gains and AI adoption. Key risks include high debt levels, negative cash flow, and competitive pressures in the communications software sector that could challenge margin expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →
